EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

COMbination therapy with baloxavir and oseltamivir 1 for hospitalized patients with influenza: The pragmatic COMBO 1 randomized controlled trial

Jennifer Victory, Melissa Scribani iD, Amanda Hasuly, Paul Jenkins, Nicole Krupa, Erik Riesenfeld, Dikshya Khatiwada, Ahmad Raja, Summia Afridi, Azkia Khan, Armando S Paez, Akram Khan iD und 1 weitere

Antiviral Therapy · 2026

DOI: 10.1177/13596535261479944 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Antiviral Therapy, 2026. Verfasst von Jennifer Victory und 12 weiteren Autor:innen. Beteiligte Einrichtung: Bassett Research Institute, Bassett Medical Center, Cooperstown, NY, USA. Hauptthemen laut MEDLINE: Oseltamivir, Influenza, Human, Dibenzothiepins, Triazines. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

COMBO 1 compared time to cessation of viral shedding (TCVS) among hospitalized influenza patients treated with oseltamivir plus a single dose of baloxavir vs. oseltamivir alone.

Methods

In a quadruple-blinded, placebo-controlled parallel group multicenter randomized controlled trial, hospitalized patients with laboratory-confirmed influenza were randomly enrolled in a 1:1 ratio to Group 1 (oseltamivir+placebo) or Group 2 (oseltamivir+baloxavir). All patients were treated with oseltamivir for 5 days; one dose of baloxavir or placebo was given in identical capsules. Primary efficacy and safety outcomes were TCVS by virus titer with qCulture TCID 50 agglutination and 30-day severe adverse event (SAE) rate, respectively. Secondary virology, clinical, and safety outcomes were assessed. Continuous and categorical data were analyzed with Wilcoxon Rank-Sum and Fisher’s Exact Tests, respectively.

Results

14 participants were randomized and received study drug (Group 1: n=6, Group 2: n=8); the study was stopped early due to slow accrual. Baseline characteristics were balanced. Median TCVS with qCulture was 53.3 hours in Group 1 and 25.3 hours in Group 2 (p=0.13). 30-day overall SAE rates were 16.7% and 12.5%, respectively. All patients achieved negative qCulture. Median TCVS with quantitative PCR (RT-qPCR) was 115.6 and 34.4 hours (p=0.24); % achieving viral negative by RT-qPCR was 33.3% and 75.0% (p=0.28), respectively.

Conclusions

Combination therapy with oseltamivir and a single dose of baloxavir was inconclusive with non-significant trends towards shorter median TCVS vs. monotherapy with oseltamivir in hospitalized patients with influenza. Interpretation is limited by small sample size and early termination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OseltamivirInfluenza, HumanDibenzothiepinsTriazinesAntiviral AgentsMorpholinesPyridonesThiepinsPyridinesOxazinesHumansFemaleMaleDrug Therapy, CombinationMiddle AgedAdultTreatment OutcomeVirus SheddingHospitalizationAged

Stichwörter der Autor:innen

antiviral therapybaloxavirinfluenzamulticenter randomized controlled trialoseltamivirviral shedding

Substanzen

OseltamivirbaloxavirDibenzothiepinsTriazinesAntiviral AgentsMorpholinesPyridonesThiepinsPyridinesOxazines

Autor:innen und Institutionen

  • Bassett Research Institute, Bassett Medical Center, Cooperstown, NY, USA.
  • Department of Medicine, Bassett Medical Center, Cooperstown, NY, USA.
  • Department of Medicine, Infectious Disease, Baystate Health, Springfield, MA, USA.
  • Division of Pulmonary, Allergy and Critical Care Medicine, Oregon Health & Science University, Portland, OR, USA.
  • Department of Internal Medicine, Bassett Medical Center, Cooperstown, NY, USA.

ORCID-Profile: Melissa Scribani, Akram Khan, Daniel Freilich

Förderung

  • Genentech

Zitieren

APA

Victory, J., Scribani, M., Hasuly, A., Jenkins, P., Krupa, N., Riesenfeld, E., Khatiwada, D., Raja, A., Afridi, S., Khan, A., Paez, A. S., Khan, A., & Freilich, D. (2026). COMbination therapy with baloxavir and oseltamivir 1 for hospitalized patients with influenza: The pragmatic COMBO 1 randomized controlled trial. Antiviral Therapy. https://doi.org/10.1177/13596535261479944

Vancouver

Victory J, Scribani M, Hasuly A, Jenkins P, Krupa N, Riesenfeld E, et al. COMbination therapy with baloxavir and oseltamivir 1 for hospitalized patients with influenza: The pragmatic COMBO 1 randomized controlled trial. Antiviral Therapy. 2026. doi:10.1177/13596535261479944

BibTeX
@article{Victory2026,
  author = {Victory, Jennifer and Scribani, Melissa and Hasuly, Amanda and Jenkins, Paul and Krupa, Nicole and Riesenfeld, Erik and Khatiwada, Dikshya and Raja, Ahmad and Afridi, Summia and Khan, Azkia and Paez, Armando S and Khan, Akram and Freilich, Daniel},
  title = {COMbination therapy with baloxavir and oseltamivir 1 for hospitalized patients with influenza: The pragmatic COMBO 1 randomized controlled trial},
  journal = {Antiviral Therapy},
  year = {2026},
  doi = {10.1177/13596535261479944}
}
Kostenlos starten →